Schrödinger Options Volume Surges, Signaling Bullish Bets on Near-Term Catalyst

Heavy and targeted call option volume in Schrödinger Inc. (NASDAQ: SDGR) on Friday suggests traders are positioning for a significant upward move in the near future, despite a modest pullback in the stock's price after a powerful rally.

Fresh Bullish Positioning Emerges

While Schrödinger's stock traded at $29.14, down 3.64% intraday on September 18, options data revealed a surge in bullish activity targeting strikes well above the current price. The most notable activity was in contracts expiring in October.

• October 16 $32.50 Calls: Saw 1,313 contracts traded against a pre-existing open interest of just 45. This high volume-to-open-interest ratio strongly indicates new positions being established.
• October 16 $35 Calls: Were also highly active, with 1,548 contracts changing hands versus an open interest of 397.

This pattern of buying out-of-the-money calls points to conviction that the stock could rally more than 11% to clear the $32.50 level by mid-October. The overall call-to-put volume ratio was approximately 7-to-1, underscoring the overwhelmingly bullish sentiment in the derivatives market, according to an analysis by Investing.com.

Volatility Data Signals Upside Demand

Ad

Further analysis of the options market reveals unusual pricing dynamics. The stock's three-month implied volatility stands at an elevated 83.32%, meaning options are expensive and pricing in the potential for a large price swing.

More telling is the volatility skew, which measures the relative demand for bullish calls versus bearish puts. For Schrödinger, the skew is nearly flat to slightly negative, which is uncommon for a biotechnology company. Typically, such stocks exhibit a positive skew, as investors pay a premium for puts as downside protection. The current dynamic suggests that strong demand for calls is keeping the price of upside bets unusually high relative to puts.

Context for the Trade

The aggressive call buying comes after an explosive run for the stock, which has gained over 84% in the past three months. That rally was reportedly linked to positive developments from its Q1 2026 earnings, including a partnership with Novartis and significant collaborative R&D activities.

The current options flow, characterized by fresh buying of out-of-the-money calls, is consistent with trader anticipation of a new, unannounced catalyst. Such catalysts in the biotech sector often include new partnership announcements, positive clinical trial data, or favorable FDA milestones.